Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Merck’s second quarter performance aligned with Wall Street’s revenue expectations but drew a negative reaction from the ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

Merck & Co., Inc. (NYSE: MRK) is one of the best depressed stocks to buy in 2025. On August 2, the company completed the ...

The pharmaceutical giant's journey with Celonis has evolved from operational efficiency to enabling enterprise AI ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and ...

We recently published 13 Stocks That Jim Cramer Recently Talked About. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim ...

Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts ...

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...